Summary
CVS Health Corporation reported solid revenue growth for the third quarter and first nine months of 2014, driven by increases in both its Pharmacy Services and Retail Pharmacy segments. Net revenues rose by 9.7% for the quarter and 8.9% year-to-date. While gross profit increased in dollar terms, the gross profit margin slightly decreased due to a shift in business mix towards the lower-margin Pharmacy Services segment. A significant event impacting profitability was a substantial loss of $521 million on the early extinguishment of debt, related to a $2.0 billion tender offer for senior notes. Despite this, the company continued to execute its share repurchase program, buying back approximately $2.8 billion in stock year-to-date. The company also completed the acquisition of Coram LLC for approximately $2.1 billion, which is expected to bolster its specialty infusion services. Looking ahead, CVS Health faces ongoing pressures from generic drug introductions and reimbursement rate changes, but benefits from favorable industry trends like an aging population and expanded insurance coverage under the Affordable Care Act. The company maintains a strong liquidity position and believes its operating cash flows will be sufficient to fund future initiatives.
Financial Highlights
56 data points| Revenue | $35.02B |
| Cost of Revenue | $28.55B |
| Gross Profit | $6.47B |
| Operating Expenses | $4.22B |
| Operating Income | $2.25B |
| Interest Expense | $158.00M |
| Net Income | $948.00M |
| EPS (Basic) | $0.82 |
| EPS (Diluted) | $0.81 |
| Shares Outstanding (Basic) | 1.16B |
| Shares Outstanding (Diluted) | 1.16B |
Key Highlights
- 1Net revenues increased by 9.7% to $35.0 billion for the third quarter and 8.9% to $102.3 billion for the nine months ended September 30, 2014.
- 2A significant $521 million loss was incurred due to the early extinguishment of debt from a tender offer on senior notes.
- 3The company repurchased $2.8 billion of its common stock year-to-date under its share repurchase programs.
- 4Acquisition of Coram LLC for approximately $2.1 billion was completed in January 2014, strengthening the Pharmacy Services segment.
- 5Gross profit margin slightly compressed to 18.5% for the quarter and 18.3% for the nine months, impacted by a shift towards the lower-margin Pharmacy Services segment.
- 6Pharmacy Services segment saw revenue growth driven by specialty pharmacy and network claims, while Retail Pharmacy segment benefited from store expansion and pharmacy same-store sales.
- 7Generic dispensing rates continued to increase, reaching 82.5% for the quarter in the Pharmacy Services segment and 83.3% in the Retail Pharmacy segment.